Evolus(NASDAQ) EOLS

Market Cap$540.29M

Since IPO (2018)-29%

5 Year-22%

1 Year+22%

1 Month+43%

$8.17

+5.15%

+0.40Today

After hours$8.16-$0.01 (-0.12%)

Evolus last closing stock price
Metric	Price	Date
Last close	USD 8.18	2026-08-18

Evolus stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1.92%	USD 8.34	2026-08-11
1 month	+42.76%	USD 5.73	2026-07-17
3 month	+24.13%	USD 6.59	2026-05-20
Year to date	+23.01%	USD 6.65	2025-12-31
1 year	+22.27%	USD 6.69	2025-08-18
3 year	-14.08%	USD 9.52	2023-08-18
5 year	-22.1%	USD 10.50	2021-08-19
Since inception	-28.87%	USD 11.50	2018-02-08

Evolus Financials at a Glance

Market Cap

$540.29M

Revenue (TTM)

$316.49M

Net Income (TTM)

-$34.33M

EPS (TTM)

-$0.53

P/E Ratio

-15.52

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$8.17

Volume

204.27

Open

$7.81

Price

$8.17

Volume

204.27

Open

$7.81

Previous Close

$8.18

Daily Range

$7.81 - $8.27

52-Week Range

$3.86 - $8.43

Estimated Earnings Date

Nov 4, 2026

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$8.17

Volume

204.27

Open

$7.81

Previous Close

$8.18

Daily Range

$7.81 - $8.27

52-Week Range

$3.86 - $8.43

Estimated Earnings Date

Nov 4, 2026

EOLS News

Page 1

EOLS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evolus

Evolus helps people look younger by reducing wrinkles. It sells beauty products to doctors for their patients. Consumers pay for these treatments with their own money.

What's in the Aesthetic Bag?

Jeuveau: Purified botulinum toxin treatment for frown lines; also sold as Nuceiva outside the United States.
Evolysse: Range of injectable facial gels for smoothing wrinkles and nasolabial folds.
Service Revenue: Income generated from an agent relationship with a distribution partner in Canada.

Strategic Moves and Partnerships

Partnered with Symatese to distribute five injectable gel product candidates in the United States.
Launched two new facial gel products in the United States in April 2025.
Modified a loan agreement with Pharmakon in May 2025 to increase available funding to $250 million.
Entered a $30 million credit agreement with Eclipse Business Capital in March 2026.
Settled litigation with Medytox, agreeing to pay royalties on toxin sales until September 2032.

The Evolus Edge

The company operates in the cash-pay market where patients pay doctors directly. This model avoids the need to deal with health insurance companies for payments.

Performance by the Numbers

Net revenues reached $73.1 million in Q1 2026, up 6.7% from Q1 2025.
Net loss narrowed to $10.7 million in Q1 2026, an improvement of 43.5% year-over-year.
Operating loss improved to $6.8 million in Q1 2026, compared to a $15.2 million loss in Q1 2025.
Gross profit was $48.9 million in Q1 2026, up from $46.7 million in the prior year.

The Final Word

Evolus has shifted from a single-product company to a broader aesthetics platform. Its expansion into facial fillers alongside its toxin product allows it to compete more effectively in the performance beauty market.

AI Generated • May 7, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

334

CEO

David Moatazedi, MBA

Website

www.evolus.com

Headquarters

Newport Beach, CA 92660, US

EOLS Financials

Key Financial Metrics (TTM)

Gross Margin

66.25%

Operating Margin

-7.33%

Net Income Margin

-10.85%

Return on Equity

123.11%

Return on Capital

-28.51%

Return on Assets

-13.84%

Earnings Yield

-6.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$540.29M

Shares Outstanding

66.05M

Volume

204.27

Avg. Volume

842.17K

Financials (TTM)

Gross Profit

$209.67M

Operating Income

-$23.20M

EBITDA

-$10.23M

Operating Cash Flow

-$15.38M

Capital Expenditure

-$4.79M

Free Cash Flow

-$20.17M

Cash & ST Invst.

$45.17M

Total Debt

$164.80M

Evolus Performance Analysis

Evolus annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 148,616,000	49.1%
2023	2023-12-31	USD 202,085,000	36.0%
2024	2024-12-31	USD 266,274,000	31.8%
2025	2025-12-31	USD 297,176,000	11.6%

Evolus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-0.6%
Q4	2025-12-31	30.9%
Q1	2026-03-31	-19.0%
Q2	2026-06-30	15.0%

Evolus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.33	41.1%
2023	2023-12-31	USD -1.08	-18.3%
2024	2024-12-31	USD -0.81	-25.0%
2025	2025-12-31	USD -0.80	-1.5%

Evolus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	11.1%
Q4	2025-12-31	100.8%
Q1	2026-03-31	-8100.0%
Q2	2026-06-30	25.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$84.08M

+21.2%

Gross Profit

$57.18M

+26.2%

Gross Margin

68.00%

N/A

Market Cap

$540.29M

N/A

Market Cap/Employee

$1.54M

N/A

Employees

350

N/A

Net Income

-$8.05M

+53.0%

EBITDA

-$4.03M

+48.5%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$45.17M

-26.8%

Total Debt

$164.80M

+6.4%

Accounts Receivable

$62.38M

+30.8%

Inventory

$40.90M

+54.6%

Long Term Debt

$162.23M

+6.4%

Short Term Debt

$2.57M

+7.6%

Return on Assets

-13.84%

N/A

Return on Invested Capital

-15.54%

N/A

Free Cash Flow

-$2.36M

+91.3%

Operating Cash Flow

-$3.59M

+85.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

NGNENeurogene Inc.

NGNENeurogene Inc.$35.67-2.75%

TOIThe Oncology Institute, Inc.

TOIThe Oncology Institute, Inc.$5.13-19.72%

AUTLAutolus Therapeutics plc

AUTLAutolus Therapeutics plc$2.29+0.44%

KMDAKamada Ltd.

KMDAKamada Ltd.$7.89+1.68%

KIDSOrthoPediatrics Corp.

KIDSOrthoPediatrics Corp.$25.50+3.24%

EHABEnhabit, Inc.

EHABEnhabit, Inc.$13.80+0.07%

TMCITreace Medical Concepts, Inc.

TMCITreace Medical Concepts, Inc.$4.45-1.11%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares

KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares$17.84-0.24%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$44.19+0.15%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$129.10-0.15%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.28+0.05%

INTCIntel

INTCIntel$96.69-0.07%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$72.53-0.05%

NOKNokia

NOKNokia$10.39-0.04%

Questions About EOLS

What is the current price of Evolus?

Evolus is trading at $8.18 per share.

What is the 52-week range for Evolus?

Over the past 52 weeks, Evolus has traded between $3.86 and $8.43.

How much debt does Evolus have?

As of the most recent reporting period, Evolus reported total debt of $164.80M.

How much cash does Evolus have on hand?

Evolus reported $45.17M in cash and cash equivalents in its most recent financial results.

What is Evolus’s dividend yield?

Evolus does not currently have a dividend yield.

Evolus(NASDAQ) EOLS

Evolus Financials at a Glance

EOLS News

Why Evolus Stock Soared Today

Evolus (EOLS) Q2 Revenue Rises 4%

Why Shares of Evolus Are Jumping Thursday

Why Evolus Shares Jumped This Week

Can Evolus Disrupt the Botox Market?

Why Evolus Stock Dived by Almost 19% Today

Here's Why Evolus Stock Tumbled 17.4% Today

Why Penn Virginia, Evolus, and Cousins Properties Slumped Today

EOLS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Evolus

What's in the Aesthetic Bag?

Strategic Moves and Partnerships

The Evolus Edge

Performance by the Numbers

The Final Word

EOLS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Evolus Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EOLS

What is the current price of Evolus?

What is the 52-week range for Evolus?

How much debt does Evolus have?

How much cash does Evolus have on hand?

What is Evolus’s dividend yield?

Premium Investing Services